Revolution Medicines Inc. (RVMD)
NASDAQ: RVMDHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
RVMD stock chart
Technical analysisKey statistics
All statistics- Market cap
- $34.87B
- EPS (TTM)
- -$9.13
- Dividend yield
- None
- 52-week range
- 71.15 – 224.31
- Day range
- 160.22 – 169.51
- Volume / Avg
- 4.74M / 2.28M
- Beta
- —
- Shares outstanding
- 216.29M
52-week range
RVMD stock today
Shares of Revolution Medicines (RVMD) finished higher on Nov 20 at $161.20, a gain of 1.11% or $1.77 per share, versus the S&P 500's 3.70% decline. Volume was 2.1x the average at 4.74M shares, a sign of unusually heavy trading. Shares are 28.1% below their 52-week high of $224.31, set on Aug 27, 2026 and 126.6% above the 52-week low of $71.15, in the middle of the past year's range.
RVMD is up 102.4% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 127.5%. Revolution Medicines has posted a net loss over the last twelve months (EPS of -$9.13), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Revolution Medicines
Company profileRevolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C).
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Mark A. Goldsmith M.D., Ph.D.
- Headquarters
- Redwood City, CA
- Employees
- 883
- IPO year
- 2020
- Website
- revmed.com
Financial highlights
Full financialsIn fiscal 2025, Revolution Medicines generated $0 in revenue, up 0.0% from fiscal 2024. Revolution Medicines reported a net loss of $1.13 billion, compared with a loss of $600.1 million a year earlier. Diluted earnings per share came in at -$5.95.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $11.58M | $35.38M | $29.39M |
| Growth | — | -100.00% | -67.27% | +20.38% | -31.62% |
| Net income | $-1.13B | $-600.09M | $-436.37M | $-248.71M | $-187.09M |
| EPS (diluted) | $-5.95 | $-3.58 | $-3.86 | $-3.08 | $-2.57 |
Analyst forecast
ForecastConsensus (24 analysts)
strong_buy
Avg. price target
$274.68+70.40%
- Strong buy 5
- Buy 18
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $-1.90 vs $-2.34
- Surprise
- +18.80%
RVMD news
All RVMD news- Revolution Medicines Drugged a Target Scientists Called "Undruggable" for Decades. Buy the Stock Hand Over Fist?Nasdaq
- Weekly Buzz: SNY, REGN Score Approvals; MIST Cuts Costs; ABBV, LLY, JNJ Strike DealsNasdaqABBV, BIIB, BMY, ENLV
- Why is Revolution Medicines stock rallying today?Investing.com
- Revolution Medicines Presents Updated Phase 1/2 Data for RASONQUE® (daraxonrasib) Plus Chemotherapy in First-Line Metastatic Pancreatic Cancer at ENA 2026GlobeNewswire
- Revolution Medicines Wins EU Nod for Rasonque in Pancreatic CancerNasdaqRVMD, BMY, SMMT, TNGX
- EC Approves Revolution's RASONQUE For Pancreatic Ductal Adenocarcinoma In All EU Member StatesNasdaqRVMD, ET
- European Commission Approves Revolution Medicines’ RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic CancerGlobeNewswire
- Revolution Medicines, Inc. (RVMD) Presents at Jefferies Global Healthcare Conference 2026 TranscriptSeeking Alpha
Revolution Medicines peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BIIBBiogen Inc. | 249.59 | +1.00% | $36.89B | vs RVMD |
| BNTXBioNTech SE ADR | 80.96 | -0.52% | $20.07B | vs RVMD |
| EXELExelixis Inc. | 64.63 | -1.82% | $15.77B | vs RVMD |
| NBIXNeurocrine Biosciences Inc. | 150.57 | -3.84% | $15.24B | vs RVMD |
| TECHBio-Techne Corp | 72.67 | -0.04% | $11.42B | vs RVMD |
| ARGXargenx SE ADR | 925.70 | -1.73% | $58.21B | vs RVMD |
| RGENRepligen Corporation | 163.81 | -3.81% | $10.47B | vs RVMD |
| HALOHalozyme Therapeutics Inc. | 91.35 | -1.82% | $10.41B | vs RVMD |
Indexes, lists and sector
Revolution Medicines stock FAQ
What is Revolution Medicines's stock price today?
RVMD last traded at $161.20 as of Nov 20, 4:00 PM EST, up 1.11% on the day. Prices are delayed at least 15 minutes.
Who is Revolution Medicines's CEO?
Dr. Mark A. Goldsmith M.D., Ph.D. is the chief executive officer of Revolution Medicines Inc., which has about 883 employees.
What is the RVMD 52-week high?
The 52-week high for RVMD is $224.31 and the 52-week low is $71.15. The stock is currently 28.1% below its high.